Galapagos to review future of Jyseleca

Galapagos revealed that it is weighing up all options for its only approved product, the JAK inhibitor Jyseleca. Galapagos has disclosed its financials for the first half 2023 which show that Jyseleca (filgotinib), approved in Europe for rheumatoid arthritis and ulcerative colitis, reached €54.3 million in sales, up by 54% on the like, year-earlier period but below consensus estimates.

The decline was due to the European Commission’s endorsement of the recommendation of its Pharmaceutical Risk Assessment Committee, following similar guidance in the US, to place restrictions on the use of all drugs in the JAK inhibitor class in certain patient groups including those aged 65 years or older.

The market and competitive landscape for the JAK class in Europe has changed significantly over the past six months. As a result, full-year 2023 sales guidance for Jyseleca has been cut to €100 million-€120 million from €140 million -€160 million.